Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab for MRD Eradication in Multiple Myeloma (DART4MM)
NCT03992170Phase 2Unknown
- Sponsor
- Azienda Ospedaliera Universitaria Senese
- Start
- Dec 2018
- Primary completion
- Jun 2022
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of daratumumab in multiple myeloma (MM), sponsored by Azienda Ospedaliera Universitaria Senese. Status: unknown.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03992170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03992170.